Recently looking at Pfizer, it's clearly no longer in the pandemic dividend phase, with market focus largely returning to its core business: pipeline, M&A digestion, and cash flow. The decline in vaccine and oral drug revenue is a consensus, but the company has made significant moves in cost-cutting and pipeline replenishment, resembling a slowly recovering pharmaceutical stock.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
